Impact of a guideline-based best practice alert on pneumococcal vaccination rates in adults in a primary care setting

Table 4 Vaccination rates for PCV13 and PPSV23 overall and by intervention group within the adult populations studied

Vaccination Rates	Family Med Clinics (A)				Family Med Clinics (B)				Internal Med Clinics (C)
Vaccination Rates	Baseline	Interim	Follow-up	p-value	Baseline	Interim	Follow-up	p-value	Baseline	Interim	Follow-up	p-value
High risk adults aged 19–64 years
PCV13 eligible	691	961	994		732	982	1088		1030	1369	1308
Vaccinated (n)	14	117	199	<.0001	17	135	261	<.0001	30	247	363	<.0001
Vaccinated (%)	2.03	12.17	20.02		2.32	13.75	23.99		2.91	18.04	27.75
PPSV23 eligible	734	1000	1048		785	1024	1139		1125	1395	1393
Vaccinated (n)	146	278	302	<.0001	182	260	351	0.0004	317	427	491	0.0005
Vaccinated (%)	19.89	27.80	28.82		23.18	25.39	30.82		28.18	30.61	35.25
Immunocompetent adults aged 65+
PCV13 eligible		2429	2807			2966	3724			5403	5530	<.0001
Vaccinated (n)	NA	997	1677			971	2177			2842	3778
Vaccinated (%)	NA	41.05	59.74			32.74	58.46			52.60	68.32
PPSV23 eligible	2162	1796	2167		2519	2360	2683		4799	3519	4687
Vaccinated (n)	1368	981	1219	<.0001	1356	1196	1301	0.001	3253	1999	3017	<.0001
Vaccinated (%)	63.27	54.62	56.25		53.83	50.68	48.49		67.78	56.81	64.37
Immunocompromised Adults Aged 65+
PCV13 eligible	453	578	600		452	619	684		1374	1878	1777
Vaccinated (n)	2	248	416	<.0001	4	239	440	<.0001	9	1091	1323	<.0001
Vaccinated (%)	0.44	42.91	69.33		0.88	38.61	64.33		0.66	58.09	74.45
PPSV23 eligible	516	589	637		512	642	742		1549	1894	1907
Vaccinated (n)	369	391	434	0.180	327	416	492	0.6559	1144	1303	1397	0.0011
Vaccinated (%)	71.51	66.38	68.13		63.87	64.8	66.31		73.85	68.8	73.26

ISSN: 1472-6963